PDLIM7 and post-transplant lymphoproliferative disease: In vitro-expanded EBV-specific CTLs have shown efficacy in preventing and treating post-transplant lymphoproliferative disorder (PTLD), while CAR T cells engineered to target LMP1 and LMP2 have demonstrated reduced tumor growth in both in vitro and animal studies [386,387,388].